Palmoplantar pustulosishttps://en.wikipedia.org/wiki/Pustulosis_palmaris_et_plantaris
Palmoplantar pustulosis jẹ onibaje pustular dermatosis ti nwaye loorekoore (eyini ni, pustulosis tabi psoriasis pustular) ti o wa ni agbegbe lori awọn ọpẹ ati awọn ẹsẹ nikan, ti a ṣe afihan itan-akọọlẹ nipasẹ awọn pustules intraepidermal ti o kun fun awọn neutrophils. Lilo awọn retinoids eto nikan ati ni apapo pẹlu photochemotherapy lati mu ilọsiwaju awọn aami aisan palmoplantar pustulosis.

○ Itọju
Acitretin oral jẹ doko fun iru psoriasis yii.
#Acitretin
☆ Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
  • Ni idi eyi, pompholyx tun le fura.
  • Ni laisi pustules, àléfọ ọwọ le tun jẹ ayẹwo bi ayẹwo iyatọ.
References Palmoplantar Psoriasis 28846363 
NIH
Palmoplantar psoriasis jẹ iru psoriasis ti o ni ipa lori awọ ara lori awọn ọpẹ ati awọn ẹsẹ rẹ. O ṣe afihan bi awọ ti o nipọn pẹlu boya gbigbẹ, roro, tabi apapo awọn iru mejeeji.
Palmoplantar psoriasis is a variant of psoriasis that characteristically affects the skin of the palms and soles. It features hyperkeratotic, pustular, or mixed morphologies.
 Tumor Necrosis Factor Inhibitors 29494032 
NIH
Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C), and golimumab (G), are biologic agents which are FDA-approved to treat ankylosing spondylitis (E, I, A, C, and G), Crohn disease (I, A and C), hidradenitis suppurativa (A), juvenile idiopathic arthritis (A), plaque psoriasis (E, I and A), polyarticular juvenile idiopathic arthritis (E), psoriatic arthritis (E, I, A, C, and G), rheumatoid arthritis (E, I, A, C, and G), ulcerative colitis (I, A and G), and uveitis (A).